CompletedPhase 2NCT00141765
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
Studying Nephroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan Rogel Cancer Center
- Principal Investigator
- John E. Levine, MS MDThe Univeristy of Michigan
- Intervention
- Myeloablative Chemotherapy(procedure)
- Enrollment
- 25 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 1997 – 2010
Study locations (1)
- The University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00141765 on ClinicalTrials.govOther trials for Nephroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06401330A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Children's Oncology Group
- RECRUITINGPHASE2NCT05985161A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT05384821Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)Centre Oscar Lambret
- RECRUITINGPHASE2NCT04968990Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam IrradiationSt. Jude Children's Research Hospital
- RECRUITINGNCT04423484Therapeutic Recommendations for NephroblastomaFrench Africa Pediatric Oncology Group